Shionogi & Co., Ltd. (4507)

7,923.0
-162.0(-2.00%)
  • Volume:
    3,132,000
  • Bid/Ask:
    7,923.0/7,932.0
  • Day's Range:
    7,920.0 - 8,184.0
  • Type:Equity
  • Market:Japan
  • ISIN:JP3347200002

4507 Overview

Prev. Close
8,085
Day's Range
7,920-8,184
Revenue
293.81B
Open
8,175
52 wk Range
5,372-8,439
EPS
380.09
Volume
3,132,000
Market Cap
2.39T
Dividend (Yield)
110.00
(1.36%)
Average Vol. (3m)
1,823,208
P/E Ratio
21.27
Beta
1.1
1-Year Change
41.3%
Shares Outstanding
301,483,888
Next Earnings Date
Jan 31, 2022
What is your sentiment on Shionogi & Co., Ltd.?
or
Market is currently closed. Voting is open during market hours.

Shionogi & Co., Ltd. Company Profile

Employees
5485
Market
Japan

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong SellStrong BuyStrong Buy
  • Pretty solid balance sheet.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.